SCHEMBL2881282

SCHEMBL2881282

Cc1nc2ccccc2n1Cc1ccc(C(=O)N2CC[C@@H](N3CCCC3)C2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 18/20 1.00
PTAFR P25105 1/20 0.56
HDAC1 Q13547 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2878688 1.00 HRH3 (1.00) HRH3PTAFRHDAC1HDAC6
SCHEMBL2884742 0.89 HRH3 (1.00) HRH3
SCHEMBL2886427 0.88 HRH3 (0.78) HRH3
SCHEMBL2881825 0.88 HRH3 (0.78) HRH3
SCHEMBL2882152 0.88 HRH3 (0.78) HRH3
SCHEMBL2883713 0.88 HRH3 (0.78) HRH3
SCHEMBL2878780 0.86 HRH3 (0.75) HRH3
SCHEMBL2886474 0.83 HRH3 (1.00) HRH3PTAFRHDAC1HDAC6
SCHEMBL1811575 0.83 HRH3 (1.00) HRH3
SCHEMBL2884371 0.83 HRH3 (0.71) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820825-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2010-10-26 US claimed
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists WYETH (US) 2007-09-20 US claimed
US-7820825-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2010-10-26 US disclosed
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists WYETH (US) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists HNMT, HRH4, HRH3 HRH3 3/4885PTAFR 1160/4885HDAC1 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.